S
chizophrenia is a major therapeutic challenge of modern medicine, and one of the last frontiers of brain research. The illness is defined by delusions, hallucinations, disorganized behavior, and cognitive difficulties such as memory loss. It occurs in Ϸ1% of the world population and usually first appears in early adulthood. Although antipsychotic medications have dramatically improved the lives of patients with schizophrenia, the causes of the illness remain unknown.
Of the many contemporary theories of schizophrenia, the most enduring has been the dopamine hypothesis. As originally put by Van The discovery of the antipsychotic͞ dopamine receptor (3, 4) , now commonly known as the dopamine D 2 receptor, led to repeated confirmation that it is the primary site of action for all antipsychotics (3) (4) (5) , including clozapine and quetiapine (6) . All these drugs have different potencies at the receptor. The potency depends on the drug's dissociation constant at D 2 , which, in turn, relates to the rate of release of the drug from the D 2 receptor. For example, the dopamine D 2 receptor releases clozapine and quetiapine more rapidly than it does any of the other antipsychotic drugs (7, 8) .
Given the tight correlation between the clinical potency and the D 2 -blocking action of the antipsychotic medications, dopamine overactivity could be the common denominator in the psychotic element of schizophrenia. This possibility has been actively investigated. Dopamine overactivity can be presynaptic (an excess of dopamine release from dopamine nerve terminals) or postsynaptic (an increase in the density of D 2 receptors or an increase in postreceptor action). The innovative report by Abi-Dargham et al. (2) sheds light on both pre-and postsynaptic aspects by using an indirect method to measure the levels of endogenous dopamine in patients and controls.
Although numerous postmortem studies have consistently revealed D 2 receptors to be elevated in the striata of patients with schizophrenia (9), the majority of the postmortem tissues examined have come from patients who have been treated with antipsychotics, raising the probability that the drugs themselves contributed to the elevation of D 2 (Fig. 1, Bottom) . In fact, when Abi-Dargham et al. examined the number of D 2 receptors after partially removing the obscuring effect of endogenous dopamine, the D 2 receptors were significantly elevated in schizophrenia patients as compared with control subjects. When the authors examined the data by subgroups, the results of increased receptors reached significance for previously medicated patients, but exhibited only a trend for patients who had never been medicated with antipsychotic drugs. Despite this lack of statistical significance in this latter group of patients, the empirical findings of
Schizophrenia, as compared with control subjects, also is associated with an increased releasability of dopamine (13, 14) . A high release rate of dopamine reduces the binding of radiobenzamides to tissues (15, 16) , but enhances the binding of radiospiperone (17, 18) . Competition with endogenous dopamine, as well as dopamine-induced internalization of the D 2 receptors, may account for the lessened binding of radiobenzamides to the tissue (13, 14) , because the benzamides are generally water-soluble and have less ready access to vesicle-associated receptors. Radiospiperone compounds, by contrast, are highly lipid-soluble and readily permeate cell membranes to reach internalized receptors.
In addition to the two schizophreniaassociated factors of increased D 2 receptors and increased dopamine release, there is a third factor. Dopamine D 2 receptors exist in monomer, dimer, and oligomeric forms (19) . The D 2 monomer, but not the D 2 dimer, is selectively labeled by a photolabel of radiospiperone (19) . This finding is in contrast to a benzamide photolabel (for nemonapride), which readily binds to both monomers and dimers of D 2 (19) . This important distinction between benzamides and butyrophenones may ex-plain why more D 2 receptors are detected in schizophrenia (as compared to controls) by radiospiperone, even without depletion of endogenous dopamine. This finding is illustrated in Fig. 2 , where the control individual has three D 2 receptors, two in the dimer form and one in the monomer form. It is proposed that in schizophrenia, under the influence of increased release of endogenous dopamine, all three exist in the monomer form. Thus, radioraclopride binding would show no difference, but the binding of radiospiperone would be higher in the schizophrenia brain (as compared to controls) because of an increased number of monomers.
The dopamine hypothesis has been much criticized. For instance, although therapeutic doses of most antipsychotics occupy 60% to 80% of the D 2 receptors in patients, clozapine and quetiapine have been apparent exceptions, exhibiting clinical efficacy with only 10% to 45% occupation of D 2 receptors (see references in ref. 7) . It therefore has been suggested that the dopamine hypothesis of schizophrenia be extended into a serotonin-dopamine hypothesis. However, recent work on imaging both D 2 and serotonin-2 receptors in patients taking antipsychotics fails to find evidence for a contribution from the occupation of serotonin receptors (20) . For example, the threshold for clinical antipsychotic action remains at 65% occupation of D 2 receptors in first-episode patients, whether one uses haloperidol, which has no serotonin-receptor blocking action, or risperidone or olanzapine, which block all serotonin-2 receptors but at doses far below those needed for clinical efficacy. Similarly, the threshold for extrapyramidal signs, which is Ϸ80% D 2 occupancy, remains unaltered despite the presence of 100% block of serotonin-2 receptors for risperidone or olanzapine. It should also be noted that therapeutic doses of clozapine and quetiapine transiently occupy high levels of D 2 receptors in patients, but the effect lasts for only the first few hours (6) . Thus, the D 2 -occupying properties of clozapine and quetiapine are remarkable only for their short duration of action; they otherwise support the dopamine hypothesis of schizophrenia, as originally outlined by Van Rossum (1) .
There is more to schizophrenia than psychosis. The psychological abnormalities and cognitive difficulties in schizophrenia precede and outlive the psychosis. The hypothesis of dopamine dysregulation is the best explanation for the psychotic episode in schizophrenia; the pathophysiology of other psychological and cognitive abnormalities in schizophrenia remains unclear. A combination of susceptibility genes (21) and other factors contributes to schizophrenia, and the net result dysregulates the dopamine neurotransmission system, leading to high release of dopamine, more D 2 receptors, and an apparent predominance of monomer forms of D 2 . This dopamine dysregulation leads to the psychotic episode. Further research needs to uncover underlying mechanisms that predispose the brain to the dysregulation of the dopamine system (22) . Until then, the dopamine hypothesis remains the main path to the origin and treatment of clinical signs and symptoms of psychosis in schizophrenia. 
